Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 6/20 | 0.40 |
| ▸ | ATRIP | Q8WXE1 | 4/20 | 0.40 |
| ▸ | RAF1 | P04049 | 4/20 | 0.39 |
| ▸ | BRAF | P15056 | 4/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 2/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2130229 | 1.00 | ATR (0.40) | ATRATRIPRAF1BRAFPIK3CA | |
| SCHEMBL2131386 | 0.88 | KDM4E (0.42) | RAF1BRAF | |
| SCHEMBL30796710 | 0.88 | KDM4E (0.42) | RAF1BRAF | |
| SCHEMBL19712396 | 0.86 | ATR (0.42) | ATRATRIPRAF1BRAFPIK3CA | |
| SCHEMBL2130854 | 0.86 | RAF1 (0.39) | ATRATRIPRAF1BRAFPIK3CA | |
| SCHEMBL30794713 | 0.86 | RAF1 (0.39) | ATRATRIPRAF1BRAFPIK3CA | |
| SCHEMBL2129580 | 0.86 | RAF1 (0.39) | ATRATRIPRAF1BRAFPIK3CA | |
| SCHEMBL2132941 | 0.86 | ATR (0.40) | ATRATRIPRAF1BRAFPIK3CA | |
| SCHEMBL2129803 | 0.86 | RAF1 (0.39) | ATRATRIPRAF1BRAFPIK3CA | |
| SCHEMBL30795521 | 0.85 | GBA1 (0.41) | RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |